CINRYZE® (C1 esterase inhibitor [human]) is an injectable prescription medicine that is used to help prevent swelling and/or painful attacks in children (6 years of age and older), teenagers and adults with Hereditary Angioedema (HAE).
![CINRYZE® (C1 esterase inhibitor [human]) Logo](/dist/images/hdr-logo2.webp){kind=logo}
You can do this.
With hereditary angioedema (HAE), it takes courage to embrace a preventive approach. CINRYZE® (C1 esterase inhibitor [human]) was the first FDA-approved preventive treatment that can start at age 6, helping to reduce HAE attacks earlier in life.
Start with HAE attack prevention.
Learn how CINRYZE can reduce the frequency and severity of HAE attacks in children as young as six.
Learn moreWith hereditary angioedema (HAE), it takes courage to embrace a preventive approach. CINRYZE® (C1 esterase inhibitor [human]) was the first FDA-approved preventive treatment that can start at age 6, helping to reduce HAE attacks earlier in life.
Start with HAE attack prevention.
Learn how CINRYZE can reduce the frequency and severity of HAE attacks in children as young as six.
CONSIDER STARTING ON PREVENTION
Learn about proven prevention with CINRYZE and explore resources to support your journey with HAE.
Learn about use with children
Find out more about the expanded use of CINRYZE to include children aged 6 to 11.
Learn about self-administration
Before you or your caregiver administers CINRYZE, you will need to be trained by a healthcare professional.
Get product support
OnePath® provides eligible patients prescribed a Takeda HAE therapy with dedicated Patient Support Managers to assist with your product support needs.
See our resources
Explore helpful materials to educate you and your caregiver on HAE and CINRYZE.
